ARTICLE | Company News

EC approves subcutaneous RoActemra

April 29, 2014 12:30 AM UTC

Roche (SIX:ROG; OTCQX:RHHBY) said the European Commission approved a subcutaneous formulation of RoActemra tocilizumab as monotherapy or in combination with methotrexate to treat moderate to severe rheumatoid arthritis in patients who have an inadequate response to or who are intolerant of DMARDs or TNF inhibitors. In October, FDA approved a BLA from Roche's Genentech Inc. unit for the subcutaneous formulation. ...